Prosecution Insights
Last updated: May 29, 2026

Fujirebio Inc.

4 pending office actions • 2 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready

Portfolio Summary

4
Total Pending OAs
2
Non-Final OAs
0
Final Rejections
2
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
1
Due this month
1
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (2)Due ≤ 30 days (1)Due ≤ 60 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
4
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only4 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

4
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

40 h
Manual time on pending OAs
8 h
Time saved (low, 20%)
14 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SVEIVEN, MICHAEL CAMERON 2 35.3% +38.1%
EVANS, CHRISTOPHER RYAN 1 58.8% +70.0%
DUNN, MCKENZIE A 1 57.1% +50.2%

Interview Candidates (4)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
17773748 METHOD FOR MEASURING STEROID IN URINE SAMPLE AS WELL AS KIT FOR MEASURING STEROID IN URINE SAMPLE AND NEUTRALIZING SOLUTION FOR USE IN THE METHOD SVEIVEN, MICHAEL CAMERON 124d overdue
17913363 METHOD FOR MEASURING FRAGMENTS CONTAINING HUMAN TYPE IV COLLAGEN 7S DOMAIN AND KIT FOR USE THEREIN EVANS, CHRISTOPHER RYAN 119d overdue
17915981 METHOD FOR IMMUNOASSAY OF AMYLOID BETA IN BLOOD, AND KIT FOR SAME SVEIVEN, MICHAEL CAMERON 27d
17294931 ANTIBODY CONJUGATE DUNN, MCKENZIE A 36d

Top Art Units

Art UnitApps
1678 3
1677 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
17915981 METHOD FOR IMMUNOASSAY OF AMYLOID BETA IN BLOOD, AND KIT FOR SAME SVEIVEN, MICHAEL CAMERON 1678 §103 Non-Final OA 27d Pending Sep 29, 2022
17913363 METHOD FOR MEASURING FRAGMENTS CONTAINING HUMAN TYPE IV COLLAGEN 7S DOMAIN AND KIT FOR USE THEREIN EVANS, CHRISTOPHER RYAN 1677 §103 Non-Final OA 119d overdue Pending Sep 21, 2022
17773748 METHOD FOR MEASURING STEROID IN URINE SAMPLE AS WELL AS KIT FOR MEASURING STEROID IN URINE SAMPLE AND NEUTRALIZING SOLUTION FOR USE IN THE METHOD SVEIVEN, MICHAEL CAMERON 1678 §103 Non-Final OA 124d overdue Pending May 02, 2022
17294931 ANTIBODY CONJUGATE DUNN, MCKENZIE A 1678 §103 Non-Final OA 36d Pending May 18, 2021

Managing Fujirebio Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month